BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement ("Agreement") is made as of September 26, 2017 (the "Effective Date"), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"),...Securities Purchase Agreement • October 4th, 2017 • Puissance Cross-Border Opportunities III LLC • New York
BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement ("Agreement") is made as of September 26, 2017 (the "Effective Date"), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the "Schedule of Purchasers"). Such persons and entities are hereinafter collectively referred to herein as "Purchasers" and each individually as a "Purchaser." AGREEMENT In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and each Purchaser (severally and not jointly) hereby agree as follows: SECTION 1. AUTHORIZATION OF SALE OF SECURITIES. The Company has authorized the sale and issuance of 19,449,834 shares of its Common Stock, par value $0.01 per share (the "Common Stoc
THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN...Puissance Cross-Border Opportunities III LLC • October 4th, 2017 • New York
REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of September 26, 2017, by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"), and the investors signatory...Registration Rights Agreement • October 4th, 2017 • Puissance Cross-Border Opportunities III LLC • New York
